iRhythm Holdings, Inc. reports developments for a digital health care business focused on ambulatory cardiac monitoring and arrhythmia detection. The company’s recurring updates center on the Zio ambulatory ECG portfolio, which combines patch-based monitoring, AI-powered analysis, and clinical data review to deliver cardiac rhythm insights to physicians.
Company news commonly covers quarterly and annual financial results, revenue guidance, margin trends, and operating leverage, along with clinical evidence presented at cardiology meetings. Other updates include clinician education initiatives, investor conference participation, board and governance changes, and the company’s completed transition to a holding-company structure as successor registrant to iRhythm Technologies.
iRhythm (NASDAQ:IRTC) reported real-world analyses presented at HRS 2026 showing short-duration 24–48-hour Holter monitoring misses a substantial portion of arrhythmias compared with up to 14 days of continuous Zio ambulatory ECG monitoring.
Key findings: post-ablation AF recurrence was 21% overall with 26% of first recurrences detected after 48 hours, and pregnancy monitoring found arrhythmias in 37.7% of patients with 13.6% clinically significant—most detected after 48 hours.
iRhythm Holdings (NASDAQ:IRTC) will report first quarter 2026 financial results after market close on Thursday, April 30, 2026. Management will host a conference call at 1:30 p.m. PT / 4:30 p.m. ET with a live and archived webcast available.
Investors may access the webcast via the Quarterly Results section of the company investor website at investors.irhythmtech.com.
iRhythm (NASDAQ: IRTC) reported retrospective ACC.26 analyses showing a high prevalence of clinically actionable arrhythmias across cardiometabolic and kidney-metabolic (CKM) populations and launched iRhythm Academy clinician education. Key findings: 48% arrhythmia prevalence in CKD, 47% with both diabetes+CKD, AF prevalence rose from 4.5% to 6.5% with severe obesity, adjusted AF odds ratio 2.8.
Company highlighted AI scaling in cardiology and announced a Spanish-language update to the MyZio mobile app.
iRhythm (NASDAQ: IRTC) appointed Jason Patten to its Board of Directors, effective March 12, 2026. The company said Patten brings decades of strategic healthcare leadership to support scaling toward profitability and advancing its AI-enabled, proactive care platform.
Management highlights expectations for Patten to help expand primary care access, strengthen strategic partnerships, and drive disciplined growth as iRhythm pursues a "billion-dollar platform" grounded in clinical excellence.
iRhythm (NASDAQ: IRTC) reported strong Q4 and full-year 2025 results with revenue growth, margin expansion, and improved profitability. Q4 revenue was $208.9M (+27.1% YoY); full-year revenue was $747.1M (+26.2% YoY). Q4 GAAP net income was $5.6M; FY adjusted EBITDA was $68.9M. Cash and marketable securities totaled $583.8M. The company provided 2026 guidance of $870M–$880M revenue and adjusted EBITDA margin of 11.5%–12.5%.
Management cited volume growth across US core, innovative channels, and international markets, plus first-year positive free cash flow of $34.5M.
iRhythm Holdings (NASDAQ: IRTC) will release fourth quarter and full year 2025 financial results after market close on February 19, 2026. Management will host a conference call at 1:30 p.m. PT / 4:30 p.m. ET with a live and archived webcast available on the company’s investor site.
iRhythm (NASDAQ:IRTC) provided preliminary Q4 2025 highlights and a business update at the 44th Annual J.P. Morgan Healthcare Conference. The company expects full‑year 2025 revenue to exceed the high end of prior guidance of $740 million, driven by record revenue unit volume in Q4 2025. For full‑year 2026, iRhythm projects revenue of $870–$880 million (approximately 17%–18% YoY) and an adjusted EBITDA margin of ~11.5%–12.5%. Management cited clinical evidence from >1.4 million patients supporting Zio long‑term continuous monitoring and noted free cash flow positivity in 2025. Management presented on Jan 12, 2026 at 8:15 AM PT; a live and archived webcast is available on the company investor site.
iRhythm Technologies (NASDAQ:IRTC) will present at the 44th Annual J.P. Morgan Healthcare Conference.
Management is scheduled to present on Monday, January 12, 2026 at 8:15 a.m. PT / 11:15 a.m. ET. A live and archived webcast will be available in the Events and Presentations section of the company investor website at investors.irhythmtech.com.
iRhythm Technologies (NASDAQ:IRTC) presented a large-scale analysis of 408,470 U.S. patients at APHRS 2025 showing consistent performance of the Zio® long-term continuous ECG monitoring (LTCM) system across Asian and non-Asian groups.
Key metrics: Asians were 3.4% of the cohort; median wear time 13.6 vs. 13.0 days; analyzable ECG 12.9 vs. 12.2 days; AF detection 14.0% vs. 14.3%; total arrhythmia yield 79.8% vs. 82.9%; repeat testing 14.8% vs. 15.4%. Findings support generalizability of Zio LTCM and note AI algorithm approval by PMDA for Japan use.
iRhythm Technologies (NASDAQ: IRTC) announced publication of a large real-world study in Heart Rhythm and new data presented at AHA Scientific Sessions 2025.
The Heart Rhythm analysis of >1.1 million Zio long‑term continuous monitoring (LTCM) patients found that 24–48 hour monitoring missed actionable arrhythmias (64% of daily‑symptom patients with actionable arrhythmias were undetected in the first 48 hours) and that mean time to first arrhythmia exceeded 48 hours for all arrhythmia types; symptom–rhythm correlation was 20%. AHA data across >742,000 Zio devices showed home self‑application achieved median wear >13.8 days and >98% analyzable ECG time, and CKM/CKD analyses across >10 million patients revealed earlier arrhythmia emergence across disease stages.